Cargando…

A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography

BACKGROUND: Although CT colonography is a less invasive alternative for colonoscopy for the detection of colorectal polyps and cancer, procedural pain is common. In several studies, CT colonography pain and burden is higher than in colonoscopy. Apart from discomfort, anxiety and its related stress-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Boellaard, Thierry N, van der Paardt, Marije P, Eberl, Susanne, Hollmann, Markus W, Stoker, Jaap
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339326/
https://www.ncbi.nlm.nih.gov/pubmed/22111658
http://dx.doi.org/10.1186/1471-230X-11-128
_version_ 1782231337287024640
author Boellaard, Thierry N
van der Paardt, Marije P
Eberl, Susanne
Hollmann, Markus W
Stoker, Jaap
author_facet Boellaard, Thierry N
van der Paardt, Marije P
Eberl, Susanne
Hollmann, Markus W
Stoker, Jaap
author_sort Boellaard, Thierry N
collection PubMed
description BACKGROUND: Although CT colonography is a less invasive alternative for colonoscopy for the detection of colorectal polyps and cancer, procedural pain is common. In several studies, CT colonography pain and burden is higher than in colonoscopy. Apart from discomfort, anxiety and its related stress-induced peri- procedural side effects, this may influence the adherence for CT colonography as a possible screening tool for colorectal cancer. We hypothesize that a single bolus intravenous alfentanil will give a clinically relevant reduction in maximum pain defined as at least 1.3 point reduction on an 11-point numeric rating scale (NRS). METHODS/DESIGN: A randomized double-blind placebo-controlled trial in which patients scheduled for elective CT colonography in a single tertiary centre are eligible for inclusion. The first 90 consenting patient will be block-randomized to either the alfentanil group or the placebo group. Before bowel insufflation, the alfentanil group receives a single bolus intravenous alfentanil 7.5 μg/kg dissolved in 0.9% NaCl, while the placebo group receives an intravenous bolus injection of pure 0.9% NaCl. For both groups an equal amount of fluid per kilogram (75 μL/kg) is injected. The primary outcome is the difference in maximum pain on an 11-point NRS. Secondary outcomes include: pain and burden of different CT colonography aspects, side effects, procedural time and recovery time. For the primary outcome an independent samples t-test is performed and a P value < 0.05 is considered statistically significant. DISCUSSION: This study will provide evidence whether a single bolus intravenous alfentanil gives a clinically relevant reduction in maximum pain during CT colonography. TRIAL REGISTRATION: Netherlands Trial Register (NTR): NTR2902 This trial will be conducted in accordance with the protocol and in compliance with the moral, ethical, and scientific principles governing clinical research as set out in the Declaration of Helsinki (1989) and Good Clinical Practice (GCP). The department of radiology of the Academic Medical Center of Amsterdam is responsible for the design and conduct of the trial.
format Online
Article
Text
id pubmed-3339326
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33393262012-05-01 A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography Boellaard, Thierry N van der Paardt, Marije P Eberl, Susanne Hollmann, Markus W Stoker, Jaap BMC Gastroenterol Study Protocol BACKGROUND: Although CT colonography is a less invasive alternative for colonoscopy for the detection of colorectal polyps and cancer, procedural pain is common. In several studies, CT colonography pain and burden is higher than in colonoscopy. Apart from discomfort, anxiety and its related stress-induced peri- procedural side effects, this may influence the adherence for CT colonography as a possible screening tool for colorectal cancer. We hypothesize that a single bolus intravenous alfentanil will give a clinically relevant reduction in maximum pain defined as at least 1.3 point reduction on an 11-point numeric rating scale (NRS). METHODS/DESIGN: A randomized double-blind placebo-controlled trial in which patients scheduled for elective CT colonography in a single tertiary centre are eligible for inclusion. The first 90 consenting patient will be block-randomized to either the alfentanil group or the placebo group. Before bowel insufflation, the alfentanil group receives a single bolus intravenous alfentanil 7.5 μg/kg dissolved in 0.9% NaCl, while the placebo group receives an intravenous bolus injection of pure 0.9% NaCl. For both groups an equal amount of fluid per kilogram (75 μL/kg) is injected. The primary outcome is the difference in maximum pain on an 11-point NRS. Secondary outcomes include: pain and burden of different CT colonography aspects, side effects, procedural time and recovery time. For the primary outcome an independent samples t-test is performed and a P value < 0.05 is considered statistically significant. DISCUSSION: This study will provide evidence whether a single bolus intravenous alfentanil gives a clinically relevant reduction in maximum pain during CT colonography. TRIAL REGISTRATION: Netherlands Trial Register (NTR): NTR2902 This trial will be conducted in accordance with the protocol and in compliance with the moral, ethical, and scientific principles governing clinical research as set out in the Declaration of Helsinki (1989) and Good Clinical Practice (GCP). The department of radiology of the Academic Medical Center of Amsterdam is responsible for the design and conduct of the trial. BioMed Central 2011-11-23 /pmc/articles/PMC3339326/ /pubmed/22111658 http://dx.doi.org/10.1186/1471-230X-11-128 Text en Copyright ©2011 Boellaard et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Boellaard, Thierry N
van der Paardt, Marije P
Eberl, Susanne
Hollmann, Markus W
Stoker, Jaap
A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography
title A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography
title_full A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography
title_fullStr A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography
title_full_unstemmed A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography
title_short A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography
title_sort randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in ct colonography
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339326/
https://www.ncbi.nlm.nih.gov/pubmed/22111658
http://dx.doi.org/10.1186/1471-230X-11-128
work_keys_str_mv AT boellaardthierryn arandomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography
AT vanderpaardtmarijep arandomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography
AT eberlsusanne arandomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography
AT hollmannmarkusw arandomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography
AT stokerjaap arandomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography
AT boellaardthierryn randomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography
AT vanderpaardtmarijep randomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography
AT eberlsusanne randomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography
AT hollmannmarkusw randomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography
AT stokerjaap randomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography